Abbott Laboratories  

(Public, NYSE:ABT)   Watch this stock  
Find more results for abt
44.26
+0.86 (1.98%)
Dec 17 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 43.41 - 44.36
52 week 35.65 - 46.10
Open 43.47
Vol / Avg. 5.05M/4.69M
Mkt cap 65.62B
P/E 40.55
Div/yield 0.24/2.17
EPS 1.09
Shares 1.51B
Beta 0.37
Inst. own 69%
Jan 20, 2015
Q4 2014 Abbott Laboratories Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 11, 2014
Abbott Laboratories at Credit Suisse Healthcare Conference
Oct 22, 2014
Q3 2014 Abbott Laboratories Earnings Release
Oct 22, 2014
Q3 2014 Abbott Laboratories Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 8.62% 10.91%
Operating margin 14.32% 12.03%
EBITD margin - 20.49%
Return on average assets 4.20% 4.33%
Return on average equity 7.59% 9.18%
Employees 69,000 -
CDP Score - 84 B

Address

C/O TAX DEPT D367 & AP6D 100 Abbott Park Road
ABBOTT PARK, IL 60064-3500
United States - Map
+1-847-9376100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of healthcare products. The Company�s business segments include established pharmaceutical products, which include gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products, and respiratory drugs and vaccines; diagnostic products, which include a range of diagnostic systems and tests manufactured, marketed and sold worldwide to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, government agencies, alternate-care testing sites and plasma protein therapeutic companies; nutritional products, which include a range of pediatric and adult nutritional products manufactured, marketed and sold worldwide, and vascular products, which include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease manufactured, marketed and sold across the world.

Officers and directors

Miles D. White Chairman of the Board, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Thomas C. Freyman Chief Financial Officer, Executive Vice President - Finance
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Hubert L. Allen Executive Vice President, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
Stephen R. Fussell Executive Vice President - Human Resources
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard W. Ashley Executive Vice President - Corporate Development
Age: 70
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Brian J. Blaser Executive Vice President - Diagnostics Products
Age: 49
Bio & Compensation  - Reuters
John M. Capek Ph.D. Executive Vice President - Medical Devices
Age: 52
Bio & Compensation  - Reuters
Michael J. Warmuth Executive Vice President - Established Pharmaceuticals
Age: 51
Bio & Compensation  - Reuters
Jaime Contreras Senior Vice President - Core Laboratory Diagnostics, Commercial Operations
Age: 57
Bio & Compensation  - Reuters
Georges H. De Vos Senior Vice President - Established Pharmaceuticals, Emerging Markets
Age: 55
Bio & Compensation  - Reuters